Evidence map›Paper›PMID 22515115›Full record

ArticleNagoya journal of medical science2012

A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in Japan.

Yoshiaki Ikeda, Takayoshi Mamiya, Hideki Nishiyama, Shiho Narusawa, Takenao Koseki, Akihiro Mouri, Toshitaka Nabeshima

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Nagoya journal of medical science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Enhancing US-Japan cooperation to combat antimicrobial resistance.Biosecurity and bioterrorism : biodefense strategy, practice, and science
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshiaki IkedaDepartment of Pharmacy, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
Takayoshi Mamiya
Hideki Nishiyama
Shiho Narusawa
Takenao Koseki
Akihiro Mouri
Toshitaka Nabeshima

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some drug management systems have been established in Japanese hospitals to reduce medical costs and regulate drug usage. Among the many available prescription drugs, antimicrobials should be given special attention because their inappropriate use often leads to sudden outbreaks of resistant bacteria. As drug specialists, pharmacists should monitor the use of all drugs, particularly antimicrobials. Carbapenems are a class of broad-spectrum antimicrobials that are widely used to treat infections worldwide. However, their inappropriate use has led to an increase in the incidence of drug-resistant bacteria and consequently, medical costs, at hospitals. To reduce inappropriate use and drug resistance, we have established a permission system to control the use of carbapenems at the Japanese Red Cross Nagoya Daiichi Hospital. In this study, we retrospectively evaluated the applicability of the new permission system compared to that of the notification system and the non control system for 14 months each. The two management systems were able to maintain total antibiotic use density and control the outbreak of drug-resistant bacteria (P. aeruginosa, E. coli, and K. pneumoniae). The number of carbapenem prescriptions was decreased dramatically when this permission system was enforced. Compared to the non control system, the cost of antimicrobials was reduced by $757,470 for the 14-month study period using the permission system. These results suggest that our system to control the use of antimicrobials can efficiently suppress the incidence of drug-resistant bacteria and medical costs at hospitals.

Indexed as

Drug CostsDrug Resistance, BacterialHospital CostsAnti-Bacterial AgentsCarbapenemsCost-Benefit AnalysisDrug UtilizationEscherichia coli InfectionsFeasibility StudiesHospitals, GeneralHumansInappropriate PrescribingInfection ControlJapanKlebsiella InfectionsMedical Order Entry SystemsAnti-Bacterial AgentsCarbapenems

Identifiers

PMID22515115
PMCPMC4831254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.